Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study

By afschroeder • November 6, 2025

Rogers KA, Yan P, Flinn IW, Stephens DM, Kipps TJ, Larson SM, Martz L, Chen X, Wang H, Hopping E, Bundschuh R, Turkoglu A, Lozanski G, McGarry C, Acosta A, Sechaud R, Baldoni D, Chaudhury A, Whalen J, Hassounah NB, Orwitz N, Otero J, Woo J, Byrd JC. Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study. Clin Cancer Res. 2025 Nov 6:OF1-OF14. doi: 10.1158/1078-0432.CCR-25-0210. Epub ahead of print. PMID: 41194375.

Tags: Hematology/Oncology, Publications

Low-Grade B-cell Lymphoma in Primary Sjögren’s Syndrome: A Case Report

Aung T, Botten G, Munteanu A, Naini BV, Pastizzo A, Kahlon KS. Low-Grade B-cell Lymphoma in Primary Sjögren's Syndrome: A Case Report. Cureus. 2025 Dec[...]

Metastatic Uveal Melanoma Surveillance: A Delphi Panel Consensus

Alban J, Bowen RC, Reichstein DA, McKean M, Lutzky J, Weis E, Carvajal RD, Dulka S, Morse BG, Butler MO, Rapisuwon S, Kim KB, Chandrasekaran[...]

The Next Chapter of Cancer Immunology Research

Jaffee EM, Ribas A. The Next Chapter of Cancer Immunology Research. Cancer Immunol Res. 2026 Jan 8;14(1):8-9. doi: 10.1158/2326-6066.CIR-25-1391. PMID: 41502310.